ICMR to test efficacy of two medicines for tackling drug-resistant TB

Tuesday, May 16, 2017

New Delhi: The Indian Council of Medical Research (ICMR) is planning to test the efficacy of two medicines — Metformin and Bedaquiline Delaminate — for tackling the drug-resistant tuberculosis.

Metformin is widely used to treat type-II diabetes. ICMR now plans a clinical trial to examine its effectiveness in fighting the TB microbe following encouraging scientific results from Indian biologists, reports Deccan Herald.

Bedaquiline, which received the US Food and Drug Administration’s approval in 2012 for the treatment of drug-resistant TB cases, is yet to be used in India’s public-funded national TB control programme.

The Metformin trial is expected to start in a couple of months, while the Bedaquiline trial may take about six months to kick off, according to ICMR director general Dr Soumya Swaminathan.

Categories: NEWS, Pharmaceuticals

Tags: , , , ,

  More from NEWS

World No Tobacco Day celebrated at ESIC Medical College


Pune doctors perform India’s first uterus transplant surgery


ICMR to test efficacy of two medicines for tackling drug-resistant TB


PGI Chandigarh to have two deans, one for academics and another for research


Hospital fined Rs 7 lakh for not taking consent before inserting catheter in a patient


Doctor with ‘poor vision’ who removed woman’s ovary instead of appendix barred from practising medicine

1 Comment »

Comment by shivani gour
2017-05-30 19:46:03

90 percent of population grows up deficient in Vitamin D3, which is involved in keeping our immune system intact. Yet no study mentions this as its not lucrative enough and plus supplementation will genuinely improve health )Which may not be the real aim of those who fund)

 
Name (required)
E-mail (required - never shown publicly)
URI
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> in your comment.